Herein, we present the efficacy of first‐line ICI in patients with NSCLC against KRAS, MET, FGFR, RET, BRAF, and HER2 driver alterations confirmed by next‐generation sequencing (NGS) in a real‐world setting. This evidence concerns the gene RET and non-small cell lung carcinoma.